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Cabozantinib for the treatment of renal 
cell carcinoma patients
ABSTRACT
Anti-angiogenesis is a key target of the first-line systemic therapy in renal cell carcinoma. Resistance to this therapy 
ultimately occurs in almost every patient who requires subsequent treatment to manage disease progression. 
Cabozantinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor and additionally 
blocking MET and AXL kinases, which are associated with tumour growth, proliferation, invasion, and resistance. 
Cabozantinib has been shown to improve overall survival, progression-free survival, and objective response rate in 
comparison to everolimus in patients with advanced renal cell carcinoma in the phase 3 METEOR study. It resulted 
in the approval for use in the treatment of advanced renal cell carcinoma following prior vascular endothelial growth 
factor (VEGF)-targeted therapy and contributed to a change of treatment guidelines, placing cabozantinib among 
second-line therapy options. Herein we discuss the biological and clinical rationale behind cabozantinib use in 
renal cell carcinoma therapy and its position in the rapidly developing renal cell carcinoma treatment landscape. 
We outline current research and future directions for renal cell carcinoma therapy. 
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Introduction
Clear-cell renal cell carcinoma (RCC) is one of the 
most challenging malignancies to treat and remains 
largely incurable. This most common form of kidney 
cancer is a cause of more than 2700 deaths every year 
in Poland and over 35,000 in the European Union [1]. 
The earliest forms of systemic therapy were based 
on immunotherapy. Understanding of angiogenesis 
mechanisms led to the development of today’s first-line 
therapies, which inhibit the vascular endothelial growth 
factor (VEGF) or the mammalian target of rapamycin 
(mTOR) pathways. Patients frequently develop resist-
ance to these therapies, as shown by disease progression. 
The median progression-free survival (PFS) was less 
than one year with first-line VEGFR tyrosine kinase in-
hibitors (TKIs) [2–4] or mTOR inhibitor [5]. Subsequent 
therapies with different drugs are the current standard 
for tumour resistance management [6–8]. Understand-
ing of resistance mechanisms led to the development of 
novel therapies, which redefine the landscape of RCC 
treatment. In recent years, drugs with new targets have 
been approved. 
The METEOR study of cabozantinib, an oral TKI 
targeting multiple distinct pathways associated with 
tumour angiogenesis, invasiveness, metastasis, and drug 
resistance, showed significant benefit in overall survival 
(OS), PFS, and objective response rate (ORR) over 
everolimus in patients with advanced RCC [9, 10]. These 
findings contributed to recent substantial modification 
of the second-line RCC treatment guidelines, [6–8] mov-
ing everolimus to the subsequent lines of treatment [11]. 
Most recently, in CABOSUN, involving patients with 
previously untreated intermediate- or poor-risk RCC, 
cabozantinib compared to standard-of-care sunitinib 
significantly increased median PFS [12]. 
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In this review, we summarise the biology of RCC, 
contributing to recent developments and accumulated 
data about cabozantinib in the treatment of RCC pa-
tients impacting current treatment guidelines. 
Renal cell carcinoma: pathophysiology, 
resistance, and therapeutic 
implications
Thanks to advances in molecular biology today, we 
understand, at least in part, the mechanisms responsible 
for the formation of cancer cells, and their proliferation 
and expansion in RCC. In most RCC cases we observe 
dysregulation of the von Hippel-Lindau (VHL) pathway 
[13]. The VHL protein is a tumour suppressor acting as 
the substrate recognition component of an E3 ubiquitin 
ligase, which in normoxic state targets the hydroxylated, 
oxygen-sensitive a-subunits of hypoxia-inducing factor 
(HIF) for ubiquitination and degradation [14–16]. VHL 
gene mutations and loss of its function lead to translo-
cation and accumulation of HIF in the nucleus, where 
it acts as a transcription factor [17]. Transcriptional 
targets of HIF include a variety of pro-tumourogenic 
genes, leading to overproduction of growth factors 
such as vascular endothelial growth factor (VEGF) and 
platelet-derived growth factor [17].
Increased VEGF gene expression [18] and VEGF 
protein levels [19] have been found in RCC and correlate 
with microvessel density [18], as a measure of the extent 
of angiogenesis. Inhibition of VEGF has been pursued 
as a therapeutic target in RCC, and subsequently 
therapies directed specifically against the VEGF protein 
(bevacizumab) and VEGF receptor kinases (sunitinib, 
pazopanib, axitinib, and sorafenib) have been developed 
in the past decade [2, 3, 20–22] and have since remained 
a standard-of-care. Other treatments include mTOR 
inhibitors (temsirolimus and everolimus) [5, 23] and the 
programmed cell death 1 (PD-1) checkpoint inhibitor 
nivolumab [24]. 
However, the majority of patients become resistant 
and require further systemic therapy. Chronic treatment 
with anti-angiogenic agents may affect tumour cells lead-
ing to upregulation of alternative tumour-survival and 
invasion pathways. Activation of the prometastatic MET 
and AXL tyrosine kinase receptors seems to be one of 
the tumour escape pathways contributing to treatment 
resistance [25]. AXL expression is directly activated 
by HIF [16] and is clinically correlated with aggressive 
tumour behaviour, poor prognosis, and increased risk 
of patient mortality [16, 26]. Direct activation of MET 
through mutations in its gene has been identified in 
hereditary, and sporadic papillary RCC [27] and its 
expression was shown in vitro to be upregulated in the 
loss of VHL function and hypoxia in clear-cell RCC [28]. 
Dysregulation of MET is involved in tumour develop-
ment, invasion, and angiogenesis [28]. Simultaneous 
inhibition of MET and VEGF signalling did not only 
decrease tumour growth but also reduced invasion and 
metastasis [29]. In vitro studies of sunitinib-induced 
resistance [25, 30–32] provide support for targeting of 
VEGFR, MET, and AXL for RCC treatment. 
Cabozantinib has a novel, multi-kinase inhibition 
mechanism of action. By blocking VEGFR 1–3 and, 
unlike other VEGRF inhibitors, additionally inhibit-
ing MET and AXL, cabozantinib targets key pathways 
important to tumour growth, metastasis, and angiogen-
esis [33] (Fig. 1). Indeed, outcomes of RCC therapy 
in clinical trials [9, 10, 12] suggest that the observed 
in vitro effects on MET and AXL may have practical 
relevance and are a step towards overcoming resistance 
to VEGFR inhibition. 
Renal cell carcinoma treatment 
landscape
The treatment landscape for RCC is dynamic and 
has changed considerably in the past year. Current 
guidelines recommend the use of several systemic 
therapies to treat patients with unresectable RCC. The 
choice of drug always depends on the context of the 
clinical course of the disease, physician experience, 
drug availability, and patient preference [34], and in 
Poland it is determined by a specific procedure called 
the therapeutic or drug program. In such programs, the 
health service provider permits treatment in selected 
diseases to well-defined groups of patients, according to 
specific inclusion/exclusion criteria and the definition of 
the dosage regimens, mode of administration, and list of 
diagnostic tests needed for qualification for the program. 
Figure 2 summarises recently updated guidelines from 
the European Society of Medical Oncology (ESMO) [6], 
the European Association of Urology (EAU) [7], and 
the National Comprehensive Cancer Network (NCCN) 
[8]. All these guidelines refer mainly to the clear cell 
histology of the RCC because most of the pivotal trials 
have been conducted in patients with this, the most com-
mon histological subtype of RCC. Guidelines differ in 
how recommendations are provided, e.g. in patient’s risk 
differentiation, reaching survival advantage outcome, 
categorisation of level of evidence and expert consensus, 
and number of lines of therapy. 
Inhibitors of VEGFR-TKI/VEGF and mTOR 
dominate in the treatment of RCC (Fig. 2). Oral 
VEGFR-TKI inhibitors such as sunitinib and pazopanib 
are established in the first-line treatment algorithm 
based on the pivotal phase 3 clinical trials [2–4] (Fig. 2). 
Temsirolimus, the mTOR inhibitor, is reserved for 
patients with poor-prognosis [5] (Fig. 2).
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Figure 1. Cabozantinib mechanism of action. VHL dysregulation promotes accumulation of HIF, resulting in expression of 
hypoxia-response genes, including VEGF, MET, and AXL. MET and AXL signalling supports tumour growth, survival, invasion, 
and metastasis also in response to VEGFR inhibition. Cabozantinib, as well as VEGFR inhibition, also blocks MET and AXL tyrosine 
kinase receptors affecting tumour escape and survival signalling pathways [24, 30]. AXL — AXL receptor; GAS6 — growth 
arrest-specific 6; HGF — hepatocyte growth factor; HIF — hypoxia-inducing factor; MET — hepatocyte growth factor receptor; 
VEGF — vascular endothelial growth factor; VEGFR — vascular endothelial growth factor receptor
The availability of drugs with different mechanisms 
of action provides multiple options for second-line 
and subsequent therapies (Fig. 2). Recently, the 
PD-1 immune checkpoint inhibitor nivolumab and the 
multi-kinase inhibitor cabozantinib showed significant 
improvement in the OS over everolimus when used 
after one or two lines of VEGF-targeted therapy(-ies) 
[9, 10, 35]. PFS was significantly improved only in the 
cabozantinib study [9, 10]. These studies significantly im-
pacted the current therapeutic landscape and increased 
the number of options for patients with advanced RCC. 
In consequence, ESMO has recently provided modi-
fied recommendations for the second-line treatment 
of RCC after initial therapy with TKIs [6]. The EAU 
recommended both cabozantinib and nivolumab after 
initial VEGFR-targeted therapy [7]. Also, based on the 
results of the CheckMate 025 [35] and the METEOR [9, 
10] studies, the NCCN panel has included cabozantinib 
and nivolumab as category 1 (high-level evidence where 
there is uniform NCCN consensus that the intervention 
is appropriate) subsequent therapy options in patients 
who previously have been treated with a TKI [8] (Fig. 2). 
As shown in phase III clinical trials, patients should pref-
erentially receive one of these agents over everolimus. 
Cabozantinib in the second-line therapy 
of renal cell carcinoma 
Cabozantinib has been approved by the European 
Commission in September 2016 for the treatment of 
advanced RCC in adults following prior vascular en-
dothelial growth factor (VEGF)-targeted therapy [36], 
based on results of the phase III METEOR randomised, 
open-label, multicentre study [9, 10].
Study design 
The study enrolled 658 adult patients with advanced 
or metastatic clear cell RCC, who had received at least 
one previous VEGFR-TKI and had documented disease 
progression on the most recent drug within six months 
before randomisation. Patients were randomly assigned 
to receive either cabozantinib (n = 330) or everolimus 
(n = 328). Everolimus was chosen as the comparator 
for cabozantinib because it was an accepted standard of 
care for the second-line treatment of advanced RCC. 
There was no limit to the number and type of previous 
therapies but patients previously treated with an mTOR 
inhibitor were not eligible for participation. Randomisa-
tion was stratified by number of prior VEGFR-TKIs and 
Memorial Sloan Kettering Cancer Centre (MSKCC) 
risk groups, commonly used in clinical trials design and 
interpretation [37]. 
Cabozantinib was given orally once a day at 60 mg, 
and everolimus was given once a day at 10 mg. Treat-
ment modification was allowed, including interruptions 
and dose reductions to manage adverse events (AEs). 
Dose reductions were permitted to 40 and then to 
20 mg for cabozantinib and to 5 and then to 2.5 mg for 
everolimus. Patients could continue treatment beyond 
progression at the investigator’s discretion, but crosso-
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Figure 2. Summary of the renal cell carcinoma systemic therapy practice guidelines
ESMO, adopted from the European Society of Medicinal Oncology Guidelines for the systemic therapy for metastatic RCC with 
clear cell histology [6]. Only standard therapy choices with highest available levels of evidence and grades of recommendation 
are presented. Levels of evidence (I–V) and grades of recommendation provided in brackets. Recommendations for therapy 
post-cytokines are not included. mTOR — mammalian target of rapamycin; TKI — tyrosine kinase inhibitor
EAU, adopted from the European Association of Urology Guidelines for clear cell renal cancers that are resistant to vascular 
endothelial growth factor receptor targeted therapy [7]. In each VEGF-resistant disease therapy line switches should be to 
options not given previously. Recommended switches are indicated by arrows between options providing or not providing 
survival advantage. a — sunitinib and pazopanib can be recommended in all Memorial Sloan Kettering Cancer Centre risk 
groups. Bevacizumab/interferon (favourable and intermediate-risk) and temsirolimus (poor-risk) have not been widely used 
as first-line therapy in the pivotal VEGF-resistant trials, and therefore recommendations are not possible; b — nivolumab and 
cabozantinib have not been given after everolimus and thus cannot be recommended above other agents; c — sorafenib has an 
inferior progression-free survival to axitinib; d — these drugs have shown a survival advantage in VEGF-resistant disease but not 
in this specific setting; e — these drugs were given after progression in the pivotal cabozantinib or nivolumab trials
NCCN, adopted from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Kidney Cancer version 
1.2017 [8]. Systemic therapy guidelines for patients with relapse and surgically unresectable cancer with predominant clear cell 
histology. NCCN believes that the best management of any patient with cancer is in a clinical trial. All recommendations include 
best supportive care. Recommendations of category 1 (high-level evidence, uniform NCCN consensus that the intervention is 
appropriate) and 2A (lower-level evidence, uniform NCCN consensus that the intervention is appropriate) are presented and listed 
alphabetically by category and preference. f — for poor-prognosis patients; g — for patients with excellent performance status 
and normal organ function; h — for selected patients; i — eligible patients should preferentially receive this agent over everolimus
ver between treatment groups was not allowed in the 
study [9, 10].
The primary endpoint of the study was PFS meas-
ured as the time from randomisation to radiographic 
progression according to the Response Evaluation 
Criteria in Solid Tumours (RECIST) or death from any 
cause. PFS and ORR were assessed by an independent 
radiology review committee. The secondary endpoints 
were OS — the time from randomisation to death from 
any cause, and objective response rate defined as the 
percentage of patients with complete or partial response 
per RECIST criteria evaluated by an independent 
radiology review. The total sample size of 650 patients 
required to evaluate OS was much larger than needed to 
assess the primary endpoint of PSF. To provide adequate 
power for all endpoint analyses and limit overrepresen-
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tation of patients with early/rapid onset of progression, 
the primary endpoint analysis (PFS) was pre-specified 
to occur when 259 PFS events had occurred in the first 
375 randomised patients (PFS population). The OS, 
ORR and also PFS were to be tested in all randomised 
patients, comprising the intention-to-treat (ITT) popula-
tion (OS population). 
Clinical efficacy of cabozantinib
Patient baseline characteristics were well balanced 
in the two treatment groups in terms of demographic 
and clinical variables. Around 70% of patients had only 
one prior therapy with VEGFR-TKI inhibitor. The 
most frequently used treatments before randomisa-
tion were sunitinib (64%) and pazopanib (44%). Most 
patients were categorised as having favourable (46%) 
or intermediate risk (42%) by MSKCC criteria. The 
median duration of follow-up for survival and safety was 
18.7 months in the cabozantinib group and 18.8 months 
in the everolimus group [9].
The PFS population analysis among the first 375 ran-
domised patients revealed PFS benefit (HR = 0.58, 95% 
CI: 0.45–0.75, p < 0.001) of cabozantinib (median PFS 
7.4 months, 95% CI: 5.6–9.1) over everolimus (median 
PFS 3.8 months, 95% CI: 3.7–5.4). In the planned in-
terim analysis for OS, the boundary of significance was 
not reached [10]. However, follow-up for OS was contin-
ued to the planned final analysis [9]. In the PFS analysis 
including all 658 patients, cabozantinib significantly 
improved PFS in comparison to everolimus with median 
PFS 7.4 vs. 3.9 months, respectively (HR = 0.51, 95% 
CI: 0.41–0.62, p < 0.0001, ITT population) [9] (Tab. 1). 
PFS reported for everolimus was similar to that reported 
in earlier trials [38]. The benefit of cabozantinib over 
everolimus was maintained regardless of the number 
of prior therapies (Tab. 1). The PFS improvements 
were demonstrated over everolimus across multiple 
subgroups, e.g. in patients with favourable and inter-
mediate MSKCC risk, patients with bone metastases, 
and patients treated with the sunitinib or pazopanib 
as the only VEGFR TKI, and by prior treatment with 
a PD-1/PD-L1 checkpoint inhibitor (Tab. 1).
In a subsequent analysis with longer follow-up, 
treatment with cabozantinib increased OS in com-
parison to treatment with everolimus, demonstrating 
a 34% reduction in the rate of death vs. comparator. 
The median OS was 21.4 months in the cabozantinib 
and 16.5 months in the everolimus group (HR = 0.66, 
95% CI: 0.53–0.83, p = 0.00026) (Tab. 1). At each time 
point of the Kaplan-Meier landmark estimates at 6, 12, 
18, and 24 months, the proportion of patients estimated 
to be alive was greater in the cabozantinib than in the 
everolimus group [9]. It is worth noting that none of 
the previously approved VEFGR-TKI inhibitors [2, 
3, 15, 39] or everolimus [23] showed OS benefit over 
comparators or placebo in second-line RCC treatment.
Assessment of the ORR showed partial responses 
in 17% of patients in the cabozantinib and 3% in the 
everolimus group (p < 0.0001). Progression as best 
Table 1. Overall survival and progression-free survival results of the METEOR study comparing cabozantinib vs. everolimus 
in the treatment of patients with advanced or metastatic RCC [9]
Outcome Cabozantinib Everolimus HR (95% CI)
no. of 
patients/events
Overall survival 330/140 328/180 0.66 (0.53–0.83)
Progression-free survival 330/180 328/214 0.51 (0.41–0.62)
Progression-free survival depending on no. prior VEGFR-TKIs
    1 235/131 229/155 0.52 (0.41–0.66)
    ≥ 2 95/49 99/59 0.51 (0.35–0.74)
Progression-free survival depending on type of previous VEGFR-TKI
    Only sunitinib 135/74 132/97 0.43 (0.32–0.59)
    Only pazopanib 88/51 83/49 0.67 (0.45–0.99)
    PD-1 or PD-1L 18/6 14/11 0.22 (0.07–0.65)
Progression-free survival depending on MSKCC risk group
    Favourable 66/34 62/37 0.47 (0.30–0.76)
    Intermediate 210/107 214/137 0.48 (0.37–0.62)
    Poor 54/39 52/40 0.67 (0.48–1.04)
MSKCC — Memorial Sloan Kettering Cancer Centre; HR — hazard ratio (value below 1 favours cabozantinib; value above 1 favours everolimus); VEGFR-TKI 
— vascular endothelial growth factor tyrosine kinase inhibitor
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response was observed in 12% of patients treated with 
cabozantinib and 27% treated with everolimus, which in-
dicates lower incidence of refractory disease in patients 
treated with cabozantinib [9]. In the case of PFS and 
ORR, the results of assessments performed by masked 
independent review committee and by investigators 
were similar [9].
The METEOR study results support the hypothesis 
that inhibition of MET and AXL targets by cabozantinib 
might overcome tumour progression and resistance to 
VEGFR-directed therapies. The question whether high 
MET expression was associated with favourable out-
comes was addressed in the study [9]. Archival or recent 
biopsied tumour tissue was obtained from around 2/3 of 
patients treated with cabozantinib or everolimus for im-
munochemistry analysis of MET protein levels. Every 
third patient had high MET expression status. The 
results suggest that the MET expression level might not 
affect outcomes with cabozantinib. One limitation of 
this analysis is that archival tissue samples were mainly 
used rather than obtaining biopsies during treatment 
[9]. Further investigation of biomarkers may help to 
define the roles of all the individual molecular targets in 
the clinical activity of cabozantinib. Finding biomarkers 
predictive of response to therapy is an unmet need in 
the RCC treatment landscape. 
Quality of life and safety profile 
Cabozantinib improved PFS, OS, and ORR [9] and 
resulted in quality of life (QoL) similar to everolimus 
in patients with advanced or metastatic RCC [40]. The 
QoL data were collected from ≥ 75% of patients using 
Functional Assessment of Cancer Therapy-Kidney 
Symptom Index (FKSI-19) and EuroQol EQ-5D-5L 
instruments. No treatment arm differences in the FKSI-
19 total score over time were observed and scores at 
the end of treatment were around seven points lower 
than at baseline in both arms. This was mainly due to 
disease progression. 
In the METEOR study, reflecting the differing 
safety profile of each drug, there were differences in the 
adverse events reported for each treatment: diarrhoea 
and nausea were more frequent for those treated with 
cabozantinib, whereas shortness of breath was worse for 
everolimus. No differences between treatments were 
observed for the other three FKSI subscales (disease-re-
lated symptom index physical, emotional, function/well-
being) or for the EQ-5D-5L questionnaire. The median 
time to deterioration defined as earlier death, progres-
sion, or ≥ 4-point decrease in FKSI disease-related 
symptom index, was longer in the cabozantinib arm than 
in everolimus group (5.5 vs. 3.7 months, p < 0.0001) [40].
Cabozantinib demonstrated a safety profile similar 
to other VEGFR-TKIs used in advanced RCC patients 
[41]. In the METEOR study, all patients in both groups 
reported adverse events (AEs). Grade 3 or 4 AEs oc-
curred in 71% of patients treated with cabozantinib 
and 60% of patients using everolimus. The most com-
mon grade 3 or 4 AEs (as per Common Terminology 
Criteria for Adverse Events) reported in the METEOR 
study were hypertension (15%), diarrhoea (13%), and 
fatigue (11%) in the cabozantinib group and anaemia 
(17%), fatigue (7%), and hyperglycaemia (5%) in the 
everolimus group. Grade ≥ 3 serious adverse events 
occurred in 39% and 40% patients in the cabozantinib 
and everolimus groups, respectively [9].
AEs were managed with dose modifications and 
supportive care. The open-label study design allowed 
for the appropriate management of AEs in both study 
groups. In the cabozantinib arm 62% of the patients 
had at least one dose reduction (median daily dose 
43 mg) and in the everolimus arm 25% of patients had 
dose reductions (median daily dose 9 mg). Treatment 
discontinuation because of AEs not related to disease 
progression occurred in 12% of cabozantinib patients 
and 11% of everolimus patients, suggesting that dose 
modifications in both treatment groups, however fre-
quent, adequately addressed the management of AEs, 
allowing a substantial number of patients to remain on 
study treatment for an extended period and preventing 
treatment-associated discontinuations. Deaths during 
the study, irrespective of causality, occurred in 8% of 
patients in the cabozantinib group and 8% of patients 
in the everolimus group. Most of these were related to 
disease progression [9]. 
Based on favourable OS, PFS, and ORR of cabo-
zantinib in comparison to everolimus, it was authorised 
as treatment for advanced RCC in Europe [36] and 
the United States [41] for the treatment of advanced 
RCC in adults following prior VEGF-targeted therapy. 
Oncology and urology associations recommended cabo-
zantinib for the treatment of RCC in the second-line 
setting [6–8]. Future research on the optimal use of 
cabozantinib and other available treatments aims to 
provide optimal care to patients with RCC.
Changes in the renal cell carcinoma 
treatment landscape: future 
implications
As described earlier, recent guidelines of RCC 
treatment will need continuous revision over the 
coming years because a range of targeted agents are 
in development. However, guidelines do not provide 
universal sequencing of treatments, since the presence 
of prognostic factors affecting OS always need careful 
sequencing of all treatments to ensure that individual 
patients receive optimum care. Further studies will 
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reveal new data on the optimal sequencing of current 
treatment options and also will allow introduction of new 
therapies. Precision treatment may become a reality in 
future therapy of RCC. 
In April 2016, nivolumab, a programmed death re-
ceptor-1 (PD-1) blocking antibody, received European 
approval for the second-line treatment of advanced 
RCC. In the CheckMate 025 study, the median OS 
was significantly longer with nivolumab vs. everolimus 
(25.0 months vs. 19.6 months, respectively), while the 
median PFS was similar in both treatment groups; 
4.6 months (95% CI 3.7–5.4) in the nivolumab group 
and 4.4 months (95% CI 3.7–5.5) in the everolimus 
group (HR 0.88; 95% CI 0.75–1.03; p = 0.11) [35]. In 
May 2016, lenvatinib, a VEGFR and FGF TKI inhibi-
tor, in combination with everolimus was approved by 
the Food and Drug Administration for the treatment 
of advanced RCC following one prior VEGF-targeted 
therapy [42]. The EMA gave its approval with the 
same indication in August 2016 [43]. The combi-
nation of lenvatinib with everolimus significantly 
prolonged investigator-assessed PFS vs. everolimus 
alone (HR 0.40, 95% CI 0.24–0.68; p = 0.0005). Pa-
tients treated with single-agent lenvatinib had a sig-
nificantly longer median PFS vs. those treated with 
single-agent everolimus (HR 0.61, 95% CI 0.38–0.98; 
p = 0.048), but PFS was not significantly different 
from the lenvatinib + everolimus combination arm 
(HR 0.66, 0.39–1.10; p = 0.12) [44]. The combination 
of targeted therapy and immunotherapy is an area of 
many ongoing trials in RCC. Another investigational 
combination therapy is ipilimumab, an anti-cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) an-
tibody, + nivolumab, which will be compared with 
sunitinib monotherapy in patients with previously 
untreated metastatic RCC in a large phase III clinical 
study [45]. Two other phase III studies are investigat-
ing anti-PD-1/PD-L1 antibodies in combination with 
axitinib [46] and bevacizumab [47] in advanced RCC. 
The hypothesis of blocking multiple pathways needed 
for tumour growth with agents having different modes 
of action inspired researchers also to combine ipili-
mumab with cabozantinib and nivolumab in different 
types of cancers, including RCC [48]. It highlights that 
novel therapeutic approaches are required to improve 
outcomes with RCC therapy. 
In parallel to the development of new treatments, 
there is also progress in investigating the optimal 
sequence of therapies. Cabozantinib and nivolumab 
effectiveness confirmed in trials [9, 10, 24] changed 
treatment guidelines in the second-line therapy of RCC 
[6–8]. Most recently, in the phase II CABOSUN study, 
cabozantinib demonstrated superiority over sunitinib 
in terms of PFS in patients with RCC previously not 
treated with systemic agents [12]. 
Conclusions
In the past decade, a number of agents have been 
approved for the first-line treatment of metastatic RCC. 
Drugs with anti-angiogenic activity are in the main-
stream of initial treatment [6–8]. Resistance may occur 
when cancer cells escape from the hypoxia induced by 
VEGF/VEGFR-targeting drugs. They adopt alterna-
tive signalling pathways to compensate for lack of this 
major angiogenic factor signalling. The development 
of new therapies aims to act on novel mechanisms of 
action, and also to target multiple pathways in parallel. 
Cabozantinib, recently approved in the treatment of 
the advanced RCC, inhibits VEGFR and targets MET 
and AXL kinases [33]. The latter are both considered as 
a possible tumour escape pathways and are involved in 
metastatic RCC pathobiology and development of resist-
ance [26, 27]. Cabozantinib treatment showed benefit 
over everolimus in patients with advanced or metastatic 
RCC, who had progressed after initial systemic therapy. 
The study met its primary endpoint — PFS improvement 
over the comparator, and also prolonged OS [9, 10], 
which is a gold standard for demonstrating clinical ben-
efit for cancer drugs [49]. Cabozantinib and nivolumab, 
a PD-1 checkpoint inhibitor, became recommended 
second-line treatments advocated by the ESMO [6], 
the EUA [7], and the NCCN [8]. However, guidelines 
[6, 7] or indirect comparisons [48] do not provide the 
answer to the crucial question regarding which agent 
should be used over the other. Additional data, such as 
real-world observational data, are needed to compare 
survival of patients under treatment with cabozantinib 
vs. nivolumab [50]. 
Most recently, cabozantinib showed improvement in 
PFS over sunitinib in a population of treatment-naïve 
patients with metastatic RCC and intermediate- or 
poor-risk disease [12]. The CABOSUN study is the first 
one that showed benefit over sunitinib in the first-line 
setting. Ongoing trials are comparing novel strategies 
used in combination with PD-1 checkpoint inhibitors or 
VEGFR-TKIs vs. sunitinib [45–47]. 
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